<DOC>
	<DOCNO>NCT00002642</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-ray kill tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness chemotherapy use cisplatin etoposide , radiation therapy , surgery , adjuvant therapy use cisplatin etoposide , treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>SWOG-9416 : Chemotherapy , Radiation Therapy , Surgery Treating Patients With Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess feasibility toxic effect 2 course cisplatin/etoposide give concurrently continuous , fractionated chest irradiation follow surgical resection boost chemotherapy patient Pancoast tumor without mediastinal supraclavicular nodal involvement . II . Assess objective response rate , resectability rate , proportion patient free microscopic residual disease treatment . OUTLINE : All patient receive Induction Regimen A , absence progression , proceed Regimen B , C. Patients refuse medically unfit surgery follow Regimen A proceed directly Regimen C. Regimen A : 2-Drug Combination Chemotherapy plus Radiotherapy . Cisplatin , CDDP , NSC-119875 ; Etoposide , VP-16 , NSC-141540 ; plus irradiation tumor ipsilateral supraclavicular region use megavoltage equipment ( photon peak energy 4-15 MV ) . Regimen B : Surgery . Tumor resection . Regimen C : 2-Drug Combination Chemotherapy . CDDP ; VP-16 . PROJECTED ACCRUAL : 99 patient accrue 2-4 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven nonsmall cell lung cancer type Selected stage IIIA/B disease ( T34 , N01 , M0 ) superior sulcus involvement , include : Apical tumor without rib vertebral body involvement , Pancoast syndrome Superior sulcus tumor involvement chest wall ( T3 ) usually rib 1 2 CT MRI , without Pancoast syndrome Superior sulcus tumor involvement vertebral body subclavian vessel ( T4 ) CT MRI , without Pancoast syndrome Pancoast syndrome define : Arm shoulder pain Neurologic finding correspond C8 T1 root inferior trunk brachial plexus , without Horner 's syndrome Single primary lesion measurable evaluable chest xray CT require Pleural effusion allow : Transudate negative cytology 2 separate thoracenteses present mediastinoscopy exploratory thoracotomy Transudate exudate negative cytology single thoracentesis present preregistration exploratory stag thoracotomy OR Present CT chest xray AND consider small tap CT ultrasound guidance Thoracoscopy assess pleural metastasis strongly recommend No mediastinal supraclavicular nodal involvement ( N23 ) establish mediastinoscopy , mediastinotomy , thoracoscopy , thoracotomy No document single multilevel ipsilateral contralateral mediastinal node whether enlarged node visible chest xray CT AP window node ( level 5 ) cause vocal cord paralysis consider N2 disease patient distinct primary tumor leave upper lobe Paralysis document indirect laryngoscopy No evidence distant metastasis follow : Chest CT , preferably contrast Thoracic spine MRI strongly recommend CT suggest vertebral body invasion Abdominal CT include liver adrenal , preferably contrast Biopsy aspiration cytology require confirm diagnosis CT MRI abnormality MRI ultrasound sufficient diagnose benign cyst hemangiomas Brain CT MRI contrast Bone scan xrays MRI , and/or aspiration cytology abnormality ( unless relate chest wall extension primary ) No pericardial effusion superior vena cava syndrome Patient consider candidate potential pulmonary resection attend thoracic surgeon PATIENT CHARACTERISTICS : Age : Adult Performance status : SWOG 02 Albumin least 0.85 time normal great 10 % tumorrelated weight loss require patient performance status 2 Hematopoietic : WBC least 4,000 Platelets least normal Hepatic : ( unless abnormality due document benign disease ) Bilirubin great 1.5 time normal ALT AST great 1.5 time normal Renal : Creatinine clearance ( calculate ) least 50 mL/min Cardiovascular : No poorly control disease , e.g . : Myocardial infarction within 3 month Active angina Arrhythmia Clinically evident congestive heart failure Pulmonary : FEV1 least 2.0 liter OR Predicted postresection FEV1 great 800 mL base quantitative lung V/Q scan DLCO least 50 % predict ( correct hemoglobin ) recommend pneumonectomy plan Other : No symptomatic peripheral neuropathy No peptic ulcer disease unless medically control Acceptance potential worsening exist clinical hearing loss No second malignancy within 5 year except : Adequately treat nonmelanomatous skin cancer Adequately treat situ cervical cancer No pregnant nursing woman Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy lung cancer Prior exploratory thoracotomy allow diagnostic staging purpose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
</DOC>